Navigation Links
Actemra (tocilizumab) Third Phase III Study Results Show,Significant Improvement in Symptoms of Patients with Rheumatoid,Arthritis

- Multinational Phase III Study Meets Primary Endpoint in Rheumatoid Arthritis Patients Who Failed to Respond to Anti-tumor Necrosis Factor Treatments -

NUTLEY, N.J., July 10, 2007 /PRNewswire/ -- Roche today announced that results from the Actemra Radiate (RheumAtoiD ArthritIs Study in Anti-TNF FailurEs) trial successfully met its primary endpoint in patients with moderate to severe rheumatoid arthritis (RA) who failed to respond to anti-tumor necrosis factor treatments (anti-TNFs).

The trial - the third multinational Phase III study of ACTEMRA outside of Japan - showed that a greater proportion of patients treated with ACTEMRA plus methotrexate (4 mg/kg or 8 mg/kg) achieved a significant reduction in the signs and symptoms of RA as evaluated by ACR20 following 24 weeks of treatment, compared to those who were treated with placebo plus methotrexate.

ACTEMRA was generally well tolerated; the most common adverse events reported more frequently in the ACTEMRA arms of the RADIATE trial were nausea, headache, nasopharyngitis, diarrhea and upper respiratory tract infection.

"The study results reconfirm the findings from the previous multinational trials that interleukin-6 receptor inhibition is a novel mechanism for reducing inflammation caused by RA," said Lars Birgerson, M.D., Ph.D., Global Head Medical Affairs, Roche. "The data demonstrate that ACTEMRA can potentially offer an effective approach in reducing the signs and symptoms of RA, particularly when therapies such as anti-TNFs prove insufficient."

Data from this trial will be submitted for presentation at upcoming national scientific meetings. In addition, other Phase III trials exploring ACTEMRA in RA are ongoing with another study scheduled to report in 2007.

About the RADIATE Study

The RADIATE (RheumAtoiD ArthritIs Study in Anti-TNF FailurEs) study is a three-arm, randomized, double-blind, placebo-controlled study
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Actemra (tocilizumab) Significantly Improves Symptoms of Rheumatoid Arthritis Compared to a Current Standard of Care
2. Neurologix to Present at the Third Annual C.E. Unterberg Towbin Emerging Growth Conference
3. Lipitor Reduced the Risk of Coronary Events by Half and Stroke by Nearly One-Third in High-Risk Patients with Type 2 Diabetes Who Experienced a Recent Stroke
4. Can-Fite Proceeds with Development of Third Drug; Progress in Development of CF502 Will Be Presented at the Annual European Congress of Rheumatology
5. One-Third of Patients Discontinue Common Breast Cancer Therapy
6. CeNeRx BioPharma Announces Positive Phase I Results in First Human Trial of Third Generation RIMA Antidepressant
7. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
8. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
9. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
(Date:9/17/2014)... Fla. , Sept. 17, 2014   myMatrixx, a pharmacy ... today that Business Insurance magazine has awarded ... distinction for the third year in a row. ... effort of Business Insurance  and the Best Companies ... is open to all publicly or privately-held insurance industry ...
(Date:9/17/2014)... Sept. 17, 2014  NuView Life Sciences, Inc. ... and collaboration agreement with Otsuka Pharmaceutical Co., Ltd. ... genomic-based diagnostic biomarker to detect cancers of the ... other future diagnostic-imaging applications. NuView retains all rights ... and in-vitro urine screen applications. Under ...
(Date:9/17/2014)... Sept. 17, 2014 Cardiac Dimensions ® ... from the TITAN II clinical trial of its ... sustained improvements in mitral regurgitation, functional improvement, quality ... safety and efficacy data, which was consistent with ... 13 at the 26 th annual Transcatheter ...
Breaking Medicine Technology:myMatrixx Honored with "Best Places to Work in Insurance" Award 2NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 2NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 3NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 4NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 5Cardiac Dimensions Announces New Long-Term Outcomes Data From TITAN II Clinical Trial Demonstrates Safety, Efficacy Of Enhanced CARILLON Mitral Contour System 2Cardiac Dimensions Announces New Long-Term Outcomes Data From TITAN II Clinical Trial Demonstrates Safety, Efficacy Of Enhanced CARILLON Mitral Contour System 3
... 4, 2011 A team of scientists at Tufts ... single-cell levels designed to detect breast cancer earlier, and ... Innovator Award from the Department of Defense Breast Cancer ... Ph.D. The Innovator Awards provide "individuals who ...
...   Research led by St. Jude Children,s Research Hospital scientists ... that are the workhorses of cells and, in the ... The discovery involves a chemical known as ... proteins have this chemical added to the amino acid ...
Cached Medicine Technology:Fighting Breast Cancer Early, One Cell At A Time 2Fighting Breast Cancer Early, One Cell At A Time 3Molecule Serves as a Key in Some Protein Interactions 2Molecule Serves as a Key in Some Protein Interactions 3
(Date:9/18/2014)... Lewisville, TX (PRWEB) September 18, 2014 ... of independent freestanding emergency rooms in the United States, ... of its new Missouri City-Lakes facility. , “We ... role as facility medical director of our new Missouri ... Director of First Choice Emergency Room. , Dr. ...
(Date:9/18/2014)... CA (PRWEB) September 18, 2014 The ... solutions, from active, to medium, and even long term ... content for any length of time. This includes media ... machine-produced data. When used together, Nautilus and ASG-Digital Archive ... archive content. , "storageFOUNDRY is pleased to work ...
(Date:9/17/2014)... The global ablation technologies market is estimated to ... 2019. Although mature markets (such as the U.S., Germany, ... ablation technologies market in 2014, the Asia-Pacific region is ... in the next five years.Factors such as increasing government ... hospitals and surgical centers, and the rising focus of ...
(Date:9/17/2014)... September 18, 2014 Dr. Shalev is a ... to Houston to study at the University of Texas, and ... studying she realized her real passion lay in dentistry, and ... from the University of Texas Health Science Center at Houston ... and is a member of The Greater Houston Dental Society, ...
(Date:9/17/2014)... 18, 2014 US medical facilities are ... medical waste in 2014. Due to public safety concerns, ... along with municipal solid waste. An increasing number of ... waste (RMW). This includes disposable items that may be ... materials. As a result of increased regulation, most small ...
Breaking Medicine News(10 mins):Health News:First Choice Emergency Room Announces Dr. Douglas J. Harrison as Medical Director of Missouri City - Lakes, Texas Facility 2Health News:storageFOUNDRY and ASG Software Solutions Partner to Integrate ASG-Digital Archive with the Nautilus Software-Defined Storage Platform 2Health News:storageFOUNDRY and ASG Software Solutions Partner to Integrate ASG-Digital Archive with the Nautilus Software-Defined Storage Platform 3Health News:9.6% CAGR for Ablation Technologies Market Globally to 2019 Says a New Research Report Available at ReportsnReports.com 2Health News:9.6% CAGR for Ablation Technologies Market Globally to 2019 Says a New Research Report Available at ReportsnReports.com 3Health News:9.6% CAGR for Ablation Technologies Market Globally to 2019 Says a New Research Report Available at ReportsnReports.com 4Health News:Medical Waste Disposal Services in the US Industry Market Research Report Now Available from IBISWorld 2Health News:Medical Waste Disposal Services in the US Industry Market Research Report Now Available from IBISWorld 3
... Diluted Earnings Per Share of $0.70; Sales Up 25%; Net Earnings ... $65 Million; Operating Cash Flow of $91 Million, ... ) reported results for the third quarter ended September 30,2007 that ... per share (DEPS) were $0.70 compared to $0.56 in,the third quarter ...
... Oct. 25 As of 1:00 p.m. PST,today, ... Miguel,Covenant Village retirement campus in Spring Valley. Emergency ... living,apartments and residents were transported to the campus ... Loma. The residents were evacuated late,Monday night. ...
... new way to treat individuals with cancer that is ... and kill cancer cells while leaving normal cells unharmed. ... study, David Kirn and colleagues at Jennerex Biotherapeutics, San ... with antitumor effects in both mice and rabbits. , ...
... Mich.---The University of Michigan is the lead research institution ... to study the health consequences on victims in disasters. ... Disaster Mental Health Research, includes researchers from U-M, Dartmouth ... and the University of Oklahoma. The center is funded ...
... Realtors testified at the Senate Finance Committee hearing today ... the needs of,its self-employed members. Nearly 30 percent of ... reason - 84 percent of Realtors who do,not have ... that tax incentives for the self-employed and for small,employers, ...
... LANSING, Mich., Oct. 25 American,Physicians Capital, Inc. (APCapital) ... million or $1.21 per diluted common share for the ... 2007, APCapital has generated,net income of $40.1 million, or ... book value per share was $25.61 based on,10,575,799 shares ...
Cached Medicine News:Health News:Roper Industries Announces Record Third Quarter Results 2Health News:Roper Industries Announces Record Third Quarter Results 3Health News:Roper Industries Announces Record Third Quarter Results 4Health News:Roper Industries Announces Record Third Quarter Results 5Health News:Roper Industries Announces Record Third Quarter Results 6Health News:Roper Industries Announces Record Third Quarter Results 7Health News:Roper Industries Announces Record Third Quarter Results 8Health News:Roper Industries Announces Record Third Quarter Results 9Health News:Roper Industries Announces Record Third Quarter Results 10Health News:U-M to lead disaster aftermath research center 2Health News:Nearly 30 Percent of Realtors(R) Lack Health Insurance 2Health News:American Physicians Capital, Inc. Reports Third Quarter 2007 Results 2Health News:American Physicians Capital, Inc. Reports Third Quarter 2007 Results 3Health News:American Physicians Capital, Inc. Reports Third Quarter 2007 Results 4Health News:American Physicians Capital, Inc. Reports Third Quarter 2007 Results 5Health News:American Physicians Capital, Inc. Reports Third Quarter 2007 Results 6Health News:American Physicians Capital, Inc. Reports Third Quarter 2007 Results 7Health News:American Physicians Capital, Inc. Reports Third Quarter 2007 Results 8Health News:American Physicians Capital, Inc. Reports Third Quarter 2007 Results 9Health News:American Physicians Capital, Inc. Reports Third Quarter 2007 Results 10Health News:American Physicians Capital, Inc. Reports Third Quarter 2007 Results 11Health News:American Physicians Capital, Inc. Reports Third Quarter 2007 Results 12Health News:American Physicians Capital, Inc. Reports Third Quarter 2007 Results 13
... incisional corneal surgery has long ... of the ophthalmology practice. To ... the technical skills and a ... quality. The new "Newman Astigmatic ...
The new TRC-NW200 Non-Mydriatic Retinal Camera combines Topcons years of experience in retinal imaging with the latest advances in digital and electronic technology....
... is indicated for the treatment of ... as telangiectasia, rosacea, spider angiomas, cherry ... papulosis nigra and keratoses. Patented ... selection of handpieces maximizes versatility, compact ...
... handpieces, used for endophotocoagulation ... with uncompromised laser treatment ... EndoProbe handpieces are compatible ... green (532 nm), OcuLight ...
Medicine Products: